| P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement MVS Varma, Y Ashokraj, CS Dey, R Panchagnula Pharmacological research 48 (4), 347-359, 2003 | 558 | 2003 |
| Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo MVS Varma, R Panchagnula European journal of pharmaceutical sciences 25 (4-5), 445-453, 2005 | 425 | 2005 |
| Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination MVS Varma, RS Obach, C Rotter, HR Miller, G Chang, SJ Steyn, ... Journal of medicinal chemistry 53 (3), 1098-1108, 2010 | 317 | 2010 |
| Development of a new permeability assay using low‐efflux MDCKII cells L Di, C Whitney‐Pickett, JP Umland, H Zhang, X Zhang, DF Gebhard, ... Journal of pharmaceutical sciences 100 (11), 4974-4985, 2011 | 293 | 2011 |
| Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems MVS Varma, AM Kaushal, A Garg, S Garg American Journal of drug delivery 2, 43-57, 2004 | 274 | 2004 |
| Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS) MV Varma, SJ Steyn, C Allerton, AF El-Kattan Pharmaceutical research 32, 3785-3802, 2015 | 272 | 2015 |
| Physicochemical determinants of human renal clearance MVS Varma, B Feng, RS Obach, MD Troutman, J Chupka, HR Miller, ... Journal of medicinal chemistry 52 (15), 4844-4852, 2009 | 219 | 2009 |
| Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport MVS Varma, K Sateesh, R Panchagnula Molecular pharmaceutics 2 (1), 12-21, 2005 | 186 | 2005 |
| pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery MV Varma, I Gardner, SJ Steyn, P Nkansah, CJ Rotter, C Whitney-Pickett, ... Molecular pharmaceutics 9 (5), 1199-1212, 2012 | 171 | 2012 |
| Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions MVS Varma, Y Lai, B Feng, J Litchfield, TC Goosen, A Bergman Pharmaceutical research 29, 2860-2873, 2012 | 147 | 2012 |
| Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance AC Rand, SSF Leung, H Eng, CJ Rotter, R Sharma, AS Kalgutkar, ... MedChemComm 3 (10), 1282-1289, 2012 | 143 | 2012 |
| Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices MVS Varma, AM Kaushal, S Garg Journal of controlled release 103 (2), 499-510, 2005 | 138 | 2005 |
| Targeting intestinal transporters for optimizing oral drug absorption M V Varma, C M Ambler, M Ullah, C J Rotter, H Sun, J Litchfield, ... Current drug metabolism 11 (9), 730-742, 2010 | 134 | 2010 |
| Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical … JA Pfefferkorn, A Guzman-Perez, J Litchfield, R Aiello, JL Treadway, ... Journal of medicinal chemistry 55 (3), 1318-1333, 2012 | 133 | 2012 |
| Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research MVS Varma, S Khandavilli, Y Ashokraj, A Jain, A Dhanikula, A Sood, ... Current drug metabolism 5 (5), 375-388, 2004 | 127 | 2004 |
| Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor … S Mathialagan, MA Piotrowski, DA Tess, B Feng, J Litchfield, MV Varma Drug Metabolism and Disposition 45 (4), 409-417, 2017 | 118 | 2017 |
| pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1 MV Varma, CJ Rotter, J Chupka, KM Whalen, DB Duignan, B Feng, ... Molecular pharmaceutics 8 (4), 1303-1313, 2011 | 117 | 2011 |
| Mechanistic modeling to predict the transporter-and enzyme-mediated drug-drug interactions of repaglinide MVS Varma, Y Lai, E Kimoto, TC Goosen, AF El-Kattan, V Kumar Pharmaceutical research 30, 1188-1199, 2013 | 114 | 2013 |
| Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state B Feng, JL LaPerle, G Chang, MVS Varma Expert opinion on drug metabolism & toxicology 6 (8), 939-952, 2010 | 113 | 2010 |
| Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future opportunities, and … KS Taskar, V Pilla Reddy, H Burt, MM Posada, M Varma, M Zheng, ... Clinical Pharmacology & Therapeutics 107 (5), 1082-1115, 2020 | 111 | 2020 |
AYMAN EL-KATTANPfizerכתובת אימייל מאומתת בדומיין pfizer.com
